CS-3150

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Severe Hypertension

Conditions

Severe Hypertension

Trial Timeline

Jun 1, 2016 → Feb 1, 2017

NCT ID

NCT02808026

About CS-3150

CS-3150 is a phase 3 stage product being developed by Daiichi Sankyo for Severe Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT02808026. Target conditions include Severe Hypertension.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02885662	Pre-clinical	Completed	Sep 1, 2016	Jul 20, 2017	Primary Aldosteronism
NCT02807974	Phase 3	Completed	Jun 1, 2016	Mar 1, 2017	Hypertension
NCT02808026	Phase 3	Completed	Jun 1, 2016	Feb 1, 2017	Severe Hypertension
NCT02807987	Phase 3	Completed	Jun 1, 2016	May 15, 2017	Hypertension With Moderate Renal Impairment
NCT02722265	Phase 3	Completed	Mar 1, 2016	Jul 8, 2017	Essential Hypertension
NCT02448628	Phase 2	Completed	May 1, 2015	Dec 1, 2015	Hypertension

Competing Products

20 competing products in Severe Hypertension

See all competitors

Product	Company	Stage	Hype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine	Pacira Biosciences	Approved	80
Drotrecogin alfa (activated)	Eli Lilly	Phase 2	52
CT-P13 SC Auto-Injector + Placebo Auto-Injector	Celltrion	Phase 3	77
CT-P17 + EU-approved Humira	Celltrion	Phase 3	77
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	77
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	77
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	77
tacrolimus	Astellas Pharma	Approved	85
enzalutamide	Astellas Pharma	Phase 1	33
Isavuconazonium Injection [Cresemba] + Placebo	Astellas Pharma	Phase 3	77
Alefacept	Astellas Pharma	Approved	85
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)	Sun Pharmaceutical	Phase 2	52
Tildrakizumab 100 mg + Placebo	Sun Pharmaceutical	Phase 3	77
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + Placebo	Sun Pharmaceutical	Phase 2/3	65
Cefiderocol	Shionogi	Approved	85
eritoran tetrasodium + Placebo	Eisai	Phase 3	77
Donepezil HCl	Eisai	Approved	85
Donepezil Hydrochloride (Aricept)	Eisai	Approved	85
KHK4827 + Placebo	Kyowa Kirin	Phase 3	77
KHK4827 + Placebo	Kyowa Kirin	Phase 3	77

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved

OAC aloneApproved

olmesartan medoxomil + Placebo + losartan potassiumApproved

Prasugrel + ClopidogrelApproved

Diet+pravastatinApproved